TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02077257

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/d compared to 10 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/d compared to 10 mg/day
Study: NCT02901457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Healthy Body Image intervention
Description: Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
Study: NCT01494831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: 15 sessions of group-based, trauma-focused cognitive behavioral therapy
Study: NCT01046305

Intervention type: BEHAVIORAL
Intervention: Interview & Questionnaires
Description: 30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.

Intervention type: BEHAVIORAL
Intervention: Rating Questionnaire
Description: Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.

Intervention type: BEHAVIORAL
Intervention: MDASI-CML Questionnaire
Description: Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
Study: NCT04109703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.
Description: The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.
Description: The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
Study: NCT04699266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assigned Intervention (POD F GF)
Description: The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
Study: NCT02750254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single dose total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT00423176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS and antibiotic
Description: MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo nasal spray plus antibiotic
Description: Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
Study: NCT04447326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy
Description: Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IC＋CCRT
Description: IC＋CCRT
Study: NCT02710799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol
Description: The informations provided in the referral list will be evaluated through the state's referrals protocols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol
Description: The informations provided in the referral list will be evaluated through the state's referrals protocols.
Study: NCT01227668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, 2-15 mg, once daily, 13-42 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 16 weeks
Study: NCT04321239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
Study: NCT02444390

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: biopsy of a metastasis
Study: NCT01965561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRoC
Description: Use of Combat Ready Clamp (CRoC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAJT
Description: Use of Abdominal Aortic and Junctional Tourniquet (AAJT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETT
Description: Use of Junctional Emergency Treatment Tool (JETT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SJT
Description: Use of SAM Junctional Tourniquet (SJT)
Study: NCT01164423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space TGC
Description: Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Study: NCT04189094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study: NCT02346838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Study: NCT00601939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (PEI)
Description: PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
Study: NCT00537758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Study: NCT00601939

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Description: ETAU contains an adherence protocol plus access to weekly support group and a resource room.
Study: NCT00537758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and BWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Study: NCT04189094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
Study: NCT02632656

Intervention type: OTHER
Intervention: Monitoring on heart failure therapy
Description: This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
Study: NCT03877055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
Study: NCT03611114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blood orange juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Study: NCT03449628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L.casei DG
Description: (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 1 capsule, b.i.d. for 12 weeks
Study: NCT01211769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUFAs
Description: Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
Study: NCT04546009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giredestrant-matched Placebo
Description: Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole-matched Placebo
Description: Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT05142059

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A
Description: The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
Study: NCT02863718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 420mg daily
Study: NCT03368092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa Inhalant Solution [Pulmozyme]
Description: Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
Study: NCT00470717

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Weekly telephone call
Description: Details of feeding and health/sickness will be obtained
Study: NCT00512070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine and melatonin
Description: In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine and melatonin
Description: In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
Study: NCT04382404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-Velpatasvir Drug Combination
Description: One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
Study: NCT03964675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseGuard
Description: A single invitational visit with a respiratory rate measurement duration of 30 minutes.
Study: NCT01134107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 6 Day (6D)
Description: Administered by infusion pump for 12 week treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 6 Day (6D)
Description: Administered by infusion pump for 12 week treatment period
Study: NCT00557544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 0,15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 0,15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen
Description: ketoprofen 1 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoprofen
Description: ketoprofen 1 mg/Kg
Study: NCT00006178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study: NCT00418886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: oral once daily tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intravenous infusion
Study: NCT01134614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT00853645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Defibrillator (S-ICD) System
Study: NCT01134614

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02602990

Intervention type: DEVICE
Intervention: SQUID™
Study: NCT04054115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil 5 MCG Injection
Description: During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
Study: NCT03469856

Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel monotherapy
Description: A multicenter, single arm, open-label trial of in patients with chronic stable angina
Study: NCT00726973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness \>100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab monotherapy
Description: 3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
Study: NCT03594981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/AdV /EBV/BKV specific T cells
Description: Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
Study: NCT00410332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: homeopathic remedy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo drug, identical in size, form and taste as treatment remedy
Study: NCT03740087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnivorous diet
Description: Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegan diet
Description: Used as a baseline for miRNA levels in blood
Study: NCT02921880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Study: NCT01859065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified anticipatory guidance
Description: Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine
Description: Routine anticipatory guidance (control)
Study: NCT05146518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive and Dignified Maternity Care
Description: The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor.